Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research

[1]  Y. Todo,et al.  Diagnostic criteria of sentinel lymph node micrometastasis or macrometastasis based on tissue rinse liquid-based cytology in gynecological cancer , 2020, International Journal of Clinical Oncology.

[2]  S. Kalnicki,et al.  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.

[3]  Amit N. Patel,et al.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.

[4]  A. Khorana,et al.  Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. , 2020, JCO oncology practice.

[5]  Xiang Chen,et al.  Clinical determinants for fatality of 44,672 patients with COVID-19 , 2020, Critical Care.

[6]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[7]  Jian Chen,et al.  Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. , 2020, JAMA cardiology.

[8]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[9]  H. Miyashita,et al.  Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City , 2020, Annals of Oncology.

[10]  E. Basch,et al.  Oncology Practice During the COVID-19 Pandemic. , 2020, JAMA.

[11]  Bolin Wang,et al.  Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis , 2020, Aging.

[12]  C. Pinto,et al.  Indications regarding the management of interventional clinical trials with drugs during the current COVID-19 emergency in Italy , 2020, ESMO Open.

[13]  A. Kishan,et al.  Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 , 2020, Advances in Radiation Oncology.

[14]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[15]  A. Ravaud,et al.  The official French guidelines to protect patients with cancer against SARS-CoV-2 infection , 2020, The Lancet Oncology.

[16]  G. Onder,et al.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.

[17]  R. Trimble.  COVID-19 Dashboard , 2020 .

[18]  Huahao Shen,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[19]  Huahao Shen,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[20]  Li Zhang,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[21]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[22]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[23]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2018 (5th edition) , 2020, Gastric Cancer.

[24]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[25]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer , 2019, International Journal of Clinical Oncology.

[26]  Y. Kodera,et al.  Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Ajani,et al.  Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma , 2019, Oncology.

[28]  T. Fujii,et al.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.

[29]  G. Honda,et al.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.

[30]  Kazuhiro Yoshida,et al.  A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) , 2018, Gastric Cancer.

[31]  G. Beretta,et al.  Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[32]  Masahiro Yoshida,et al.  Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1 , 2018, Esophagus.

[33]  D. Zylis,et al.  Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. , 2018, In vivo.

[34]  J. Meyerhardt,et al.  NCCN Guidelines Insights: Colon Cancer, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[35]  R. Labianca,et al.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.

[36]  E. Oki,et al.  A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. , 2018, European journal of cancer.

[37]  J. Tabernero,et al.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  K. Akashi,et al.  Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer , 2018, Gastric Cancer.

[39]  T. Matsushima,et al.  A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma , 2018, International Journal of Clinical Oncology.

[40]  M. Shah,et al.  Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm , 2017, Gastric Cancer.

[41]  K. Muro,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[43]  T. Bekaii-Saab,et al.  A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis , 2017, Therapeutic advances in medical oncology.

[44]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.

[45]  K. Chìn,et al.  Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer , 2016, British Journal of Cancer.

[46]  N. Sata,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.

[47]  A. Klein,et al.  Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma , 2015, Cancer Chemotherapy and Pharmacology.

[48]  T. Kawano,et al.  Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303) , 2015, Cancer science.

[49]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[50]  A. Nashimoto,et al.  Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis , 2014, The British journal of surgery.

[51]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[52]  K. Bujko,et al.  Neoadjuvant radiotherapy (5 × 5 Gy): immediate versus delayed surgery. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[53]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[54]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Y. Yatabe,et al.  Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. , 2011, Anticancer research.

[56]  M. Shinoda,et al.  A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) , 2011, Annals of Surgical Oncology.

[57]  O. Yokosuka,et al.  Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer , 2011, Cancer Chemotherapy and Pharmacology.

[58]  N. Boku,et al.  S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. , 2010, Japanese journal of clinical oncology.

[59]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[60]  A. Sato,et al.  A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). , 2009, Japanese journal of clinical oncology.

[61]  B. Uzzan,et al.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.

[62]  Anthony S Fauci,et al.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.

[63]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[64]  H. Yamana,et al.  Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  R. Ginsberg,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  William E. Patrick.  The Food and Drug Administration , 1988 .